Korea’s first homegrown GLP-1: Can Hanmi’s Eppe undercut Mounjaro and Wegovy?
Hanmi Pharmaceutical’s Eppe is poised to challenge Wegovy and Mounjaro in Korea’s fast-growing obesity drug market, with price emerging as a potentially decisive advantage. The homegrown glucagon-like peptide-1, or GLP-1, drug is expected to launch before year-end, pending approval from the Ministry of Food and Drug Safety. Hanmi has yet to announce a final price, but industry estimates suggest a four-week supply could cost around 150,000 won ($111). That would undercut the lowest prices listed